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Psychometric validation 
of the needs assessment 
tool: progressive disease in 
interstitial lung disease
ABSTRACT 
The inter-rater/test–retest reliability and 
construct validity of a palliative care needs 
assessment tool in interstitial lung disease 
(NAT:PD-ILD) were tested using NAT:PD-
ILD-guided video-recorded consultations, 
and NAT:PD-ILD-guided consultations, 
and patient and carer-report outcomes (St 
George’s Respiratory Questionnaire (SGRQ)-
ILD, Carer Strain Index (CSI)/Carer Support 
Needs Assessment Tool (CSNAT)). 11/16 items 
reached at least fair inter-rater agreement; 
5 items reached at least moderate test–
retest agreement. 4/6 patient constructs 
demonstrated agreement with SGRQ-I scores 
(Kendall’s tau-b, 0.24–20.36; P<0.05). 4/7 
carer constructs agreed with the CSI/CSNAT 
items (kappa, 0.23–20.53). The NAT:PD-ILD 
is reliable and valid. Clinical effectiveness and 
implementation are to be evaluated.
InTRoduCTIon
People with interstitial lung disease (ILD) 
are symptomatic,1 and have limited 
disease-modifying treatment options, poor 
prognosis and poor quality of life.2 Iden-
tification and management of patients 
and carers palliative care needs are rare 
despite policy directives promoting palli-
ative care,3 and availability of palliative 
interventions.4 
The validated needs assessment tool 
in cancer (NAT:PD-C) helps clinicians 
identify and address palliative needs in 
daily practice.5 We adapted, validated and 
tested the reliability of the NAT:PD-C 
for patients with ILD (NAT:PD-ILD) 
and explored implementation implica-
tions in practice. This single page guide 
prompts clinicians to assess holistic needs 
(priority prompts for specialised palliative 
care input, patients well-being, informal 
carers needs and information needs), 
triage ongoing care (directly managed, 
refer to other team member, refer to 
specialist palliative care) and also acts as 
a referral form.
MeThodS
Summary design
The initial adaptation, face and content 
validation6 and implementation work7 
are reported elsewhere. This study tested 
the psychometric properties of (1) inter-
rater and testretest reliability, and (2) 
construct validity. 
Clinicians (doctors, nurses, physiother-
apists), patients with ILD and their family 
carers were recruited from four ILD 
tertiary referral clinics.
Inter-rater and test–retest reliability
Video recordings were made of 10 
patient-clinician consultations (range of 
disease severity and carer present/absent, 
with clinicians using the NAT:PD-ILD 
to guide assessment). Clinicians were 
trained to use the NAT:PD-ILD and 
rated at least one video consultation 
(group viewing or individual viewing 
via secure online service). Clinicians 
were asked to rerate the same video 
at least 2 weeks later. Weighted Fleiss 
kappa with quadratic weights was calcu-
lated for the ratings on 10 videos (kappa 
<0=poor agreement, 00.20=slight, 
0.210.40=fair, 0.410.60=moderate, 
0.610.80=substantial, 0.81
1=almost perfect agreement).8 Data 
simulations indicated that we required 60 
paired assessment ratings to detect at least 
substantial inter-rater agreement (kappa 
>0.6) for the item 4 (Is the patient expe-
riencing unresolved physical symptoms?) 
with 80% power.
Construct validation
Trained clinicians conducted a NAT:PD-
ILD-guided clinic consultation. Patients 
completed the St Georges Respiratory 
Questionnaire (SGRQ-I) and carers 
completed the Carer Strain Index (CSI) 
and Carer Support Needs Assessment Tool 
(CSNAT). Kendalls tau-b correlation 
coefficient was calculated to determine 
the correlation between the NAT:PD-ILD 
patient well-being items and a subset of 
SGRQ-I similar constructs identified a 
priori. The prevalence and bias-adjusted 
kappa (PABAK), Cohens kappa and 
observed percentage agreement were 
used to assess agreement between the 
NAT:PD-ILD carer items and appropriate 
CSI and CSNAT constructs identified a 
priori. Data simulations indicated that a 
sample size of 65 patients would allow 
estimation of the kappa statistic for agree-
ment such that the CI would not extend 
beyond the neighbouring category.
All analyses were conducted using Stata 
V.13 (StataCorp, Stata Statistical Soft-
ware: Release 13. College Station, TX: 
StataCorp, 2013).
ReSulTS
Reliability
Fifty-three clinicians (32 doctors, 18 phys-
iotherapists, 2 clinical physiologists, 1 
nurse) participated in 64 first views across 
10 videos, with 21 testretest observations 
on four videos.
Inter-rater reliability
Eleven (69%) NAT:PD-ILD items 
reached at least fair agreement (weighted 
kappa >0.2).
Test–retest reliability
Five items exhibited at least moderate 
agreement (weighted kappa >0.4) 
(table 1).
Construct validation
Nine clinicians (six doctors, three nurses) 
and 68 patients (mean age 66, SD 10.3; 
62% men; 45 with a carer (28 partici-
pated); 35% oxygen therapy; 56% inter-
stital pulmonary fibrosis ; 80% Medical 
Research Council breathlessness 35) were 
recruited (online supplementary eTable 
1). The SGRQ-I mean summary score 
was 62.5 (SD 20.9): symptom component 
67.4 (26.1); activities component 82.1 
(23.2); impact component 51.2 (24.3). 
Scores for the carer comparator outcome 
measures are shown in online supple-
mentary eTable 2. Agreement between 
NAT:PD-ILD concerns and comparator 
outcomes is shown in table 2. Items 2 
(unresolved psychological symptoms/
loss quality of life), 3 (problems with daily 
living activities), 5 (work, financial or legal 
concerns) and 6 (health beliefs, cultural 
or social factors) of the NAT:PD-ILD 
were significantly positively correlated 
with their comparator SGRQ-I scores (r 
range 0.240.36, P<0.05). PABAK values 
comparing the NAT:PD-ILD items with 
CSI/CSNAT items were mostly positive 
(0.040.57, minimum 52% agreement); 
however, items 11 and 13 have negative 
PABAK values (interpersonal relationships 
and grief topics).
dISCuSSIon
Items within the NAT:PD-ILD demon-
strated acceptable inter-rater reliability 
and construct validation given the broad 
constructs assessed and the breadth of 
clinical experience. The constructs of 
patient-reported quality of life (SGRQ-I) 
and assessment of need are related but 
different, therefore the relatively small 
number of items rated as moderate or 
strong is unsurprising. Similarly, many 
carer-related items both on NAT:PD-ILD 
and within CSI and CSNAT capture 
areas of concern that overlap, but are not 
directly comparable. The NAT-PD-C, with 
similar psychometric properties, resulted 
in reduced patient and carer needs when 
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Table 1 Inter-rater reliability test and test–retest results, weighted kappa
nAT:Pd-Ild item
Inter-rater reliability Test–retest*
number of observations
distribution of categories†
Weighted kappa (Se) % Agreement Weighted kappa (Se) 0 1 2
1. Does the patient have a carer? 77 NA 14% 86% 0.69 (0.24) 64.3 0.00 (–)
2. Has the patient or carer requested a referral to a Specialist Palliative Care Service (SPCS)? 70 NA 9% 91% 0.82 (0.44) 72.7 −0.14 (0.28)
3. Do you require the assistance of the SPCS? 65 NA 20% 80% 0.13 (0.30) 72.7 0.23 (0.29)
4. Is the patient experiencing unresolved physical symptoms? 89 6% 38% 56% 0.49 (0.21) 96.3 0.75 (0.22)
5. Is the patient experiencing unresolved psychological symptoms? 76 36% 57% 8% 0.32 (0.16) 81.7 0.00 (0.24)
6. Does the patient have problems with daily living activities? 85 8% 54% 38% −0.07 (0.41) 79.0 −0.13 (0.19)
7. Does the patient have concerns about spiritual or existential issues? 57 79% 18% 4% 0.44 (0.30) 85.7 0.59 (0.24)
8. Does the patient have work, inancial or legal concerns? 75 83% 13% 4% 0.15 (0.58) ‡ ‡
9. From the health delivery point of view, are there health beliefs, cultural or social factors involving 
the patient or family that are making care more complex?
57 77% 21% 2% −0.55 (0.73) 85.9 −0.03 (0.21)
10. Is the carer or family distressed about the patient’s physical symptoms? 85 32% 47% 21% −0.17 (0.39) 90.8 0.65 (0.22)
11. Is the carer or family having dificulty providing physical care? 79 61% 34% 5% 0.59 (0.23) 81.6 0.10 (0.23)
12. Is the carer or family having dificulty coping with the patient’s psychological symptoms? 71 69% 30% 1% 0.36 (0.29) 94.4 0.64 (0.23)
13. Is the carer or family concerned about inancial or legal concerns? 69 93% 7% 0% 0.77 (0.24)  ‡  ‡
14. Is the carer or family experiencing problems that are interfering with their functioning or 
interpersonal relationships, or is there a history of such problems?
67 61% 37% 1% 0.21 (0.38) 41.2 −0.15 (0.22)
15. Is the carer or family experiencing unresolved psychosocial problems or feelings that are 
interfering with their well-being or functioning?
70 47% 43% 10% 0.75 (0.12) 94.7 0.78 (0.23)
16. Is the carer or family experiencing grief over the future death of the patient? 45 69% 27% 4% 0.57 (0.27) 75.0 −0.03 (0.27)
*39/53 (74%) saw only one video consultation, 13 (25%) saw two video consultations and 1 (2%) saw four video consultations, though they may have watched each video up to two times (mean (SD) 1.3 (0.6), median 1).
 †Items 1–3: 1=yes, 2=no; items 4–16: 0=none, 1=some/potential, 2=signiicant.
‡Same category assigned by every rater on both occasions; too few categories to calculate kappa statistic.
NA, not applicable; NAT:PD-ILD, needs assessment tool: progressive disease in interstitial lung disease.
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Table 2 Relationship between NAT:PD-ILD items and SGRQ-ILD comparator items, and between the NAT:PD-ILD items relating to the carer and appropriate CSI and CSNAT items
Agreement between nAT:Pd-Ild items and SGRQ-Ild comparator items
The prevalence and bias-adjusted kappa (PABAK), Cohen’s kappa and percentage of agreement between nAT:Pd-Ild items relating to the ability and well-being of the carer and appropriate CSI and 
CSnAT items
nAT:Pd-Ild
Patient well-being ‘does the 
patient have…’ The SGRQ-I comparator
Kendall’s tau-b
(Kendall’s score, Se of score, 
P value) nAT:Pd-Ild; carer items Comparator items from CSI and CSnAT n PABAK Cohen’s kappa (Se) % Agreed
4. Unresolved physical symptoms Part 1 Q1–6; part 2 section 3 
Q1–6; and part 2 section 4 Q6
0.16 (266, 163.0, P=0.10) 10. Distressed about the patient’s symptoms? CSI8: Some behaviour is upsetting.
CSI12: Feeling completely overwhelmed
CSNAT3: Managing your relative’s symptoms, including giving medicines
28 0.57 0.53 (0.19) 79
5. Unresolved psychological 
symptoms/loss quality of life?
Part 1 Q6; part 2 section 4 Q1–6; 
and part 2 section 7
0.32 (512, 158.6, P=0.001) 11. Having dificulty providing physical care? CSI3: It is a physical strain.
CSI12: Feeling completely overwhelmed
CSNAT3: Managing your relative’s symptoms, including giving medicines
CSNAT5: Providing personal care for your relative
CSNAT9: Equipment to help care for your relative
CSNAT12: Practical help in the home
28 0.14 0.23 (0.14) 57
6. Problems with daily living 
activities?
Part 2 section 2 Q1–5; part 2 
section 4 Q4+5; part 2 section 5 
Q1–5; part 2 section 6 Q1–4; and 
part 2 section 7
0.36 (588, 159.7, P<0.001) 12. Having dificulty coping with the patient’s 
psychological symptoms?
CSI7: There have been emotional adjustments.
CSI8: Some behaviour is upsetting.
CSI12: Feeling completely overwhelmed
28 0.36 0.36 (0.18) 68
7. Spiritual or existential concerns? Section 4 Q2; and part 2 section 7 0.11 (128, 129.9, P=0.33) 13. Concerned about inancial or legal issues? CSI7: There have been emotional adjustments.
CSI8: Some behaviour is upsetting.
CSI12: Feeling completely overwhelmed
27 0.41 0.31 (0.18) 70
8. Work, inancial or legal 
concerns?
Part 2 section 1 0.34 (111, 53.2, P=0.04) 14. Experiencing problems that are 
interfering with interpersonal relationships 
or functioning, or is there a history of such 
problems?
CSI11: It is a inancial strain.
CSNAT4: Your inancial, legal or work issues
28 −0.57 −0.13 (0.07) 21
9. Health beliefs, cultural or social 
factors making care delivery 
complex?
Part 2 section 4 Q1–6 0.24 (250, 108.6, P=0.02) 15. Unresolved psychosocial problems or 
feelings?
CSI4: It is conining.
CSI5: There have been family adjustments.
CSI6: There have been changes in personal plans.
CSI7: There have been emotional adjustments.
CSI9: It is upsetting to ind…has changed so much from his/her former self.
CSI10: There have been work adjustments.
CSNAT2: Having time for yourself in the day
CSNAT11: Talking with your relative about his or her Illness
27 0.04 0.17 (0.14) 52
– – – 16. Grief over the future death of the patient CSNAT13: Knowing what to expect in the future when caring for your 
relative*
26 −0.46 −0.10 (0.10) 27
*This is more of a practical question, but was the nearest construct within the CSNAT.
Levels of concern in the NAT:PD-ILD were grouped into 0=‘None’ vs 1=‘Some/potential’ + ‘Signiicant’; the CSI responses were coded 0 for ‘No’ and 1 for ‘Yes’; and the four CSNAT item responses were categorised into two groups (0=‘No’ vs 1=‘A little more’ + ‘Quite a bit more’ + ‘Very much more’). For each NAT:PD-ILD item, the 
agreement between whether or not the carer indicated at least some problems and whether or not they had a ‘1’ in any of the recoded CSI or CSNAT items they were being compared with was calculated.
CSI; Carer Strain Index; CSNAT; Carer Support Needs Assessment Tool; NAT:PD-ILD, needs assessment tool: progressive disease in interstitial lung disease; PABAK; prevalence and bias-adjusted kappa; SGRQ-ILD, St George’s Respiratory Questionnaire-interstitial lung disease.
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applied in practice; the key factor in any 
clinical tool.5
The NAT:PD-ILD is best seen as a 
communication and decision tool where 
action is thereby triggered if more 
in-depth exploration is needed, rather 
than an outcome measurement. The 
challenges of a clinical assessment and 
diagnosis are recognised as an inexact 
science with variation between clini-
cians.9 10 Study clinicians had a wide 
range of clinical experience to increase 
generalisability. Some NAT:PD-ILD 
items with poor agreement (inter-rater 
and construct) are consistent with the 
clinician participants expressed lack of 
confidence, for example, spiritual and 
existential concerns and may rather 
reflect an educational need.7
The clinician participants rated the 
videos after 1015 min of training, inter-
rater reliability is likely to improve with 
practice. Clinicians using the tool in daily 
practice will gain more experience as they 
use the tool.
Although we reached our target sample 
size for the construct validity analysis, 
we have insufficient sample for the 
carer comparisons. Also, our sample was 
convenience, not consecutive, potentially 
affecting representativeness.
The tool is yet to be tested in a clin-
ical trial to evaluate its use by clinicians 
in terms of impact on patient and carer 
experience.
ConCluSIonS
The adapted NAT:PD-ILD has adequate 
reliability and construct validation. Effec-
tiveness in clinical practice, and optimum 
implementation are yet to be evaluated 
and identified.
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